Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Apr 23;21(8):2972.
doi: 10.3390/ijms21082972.

Winnie- APCMin/+ Mice: A Spontaneous Model of Colitis-Associated Colorectal Cancer Combining Genetics and Inflammation

Affiliations

Winnie- APCMin/+ Mice: A Spontaneous Model of Colitis-Associated Colorectal Cancer Combining Genetics and Inflammation

Stefania De Santis et al. Int J Mol Sci. .

Abstract

(1) Background: Colorectal cancer (CRC) is among the best examples of the relationship between inflammation and increased cancer risk. (2) Methods: To examine the effects of spontaneous low-grade chronic inflammation on the pathogenesis of CRC, we developed a new murine model of colitis-associated cancer (CAC) by crossing Mucin 2 mutated mice (Winnie) with ApcMin/+ mice. (3) Results: The resulting Winnie-ApcMin/+ model combines an inflammatory background with a genetic predisposition to small intestinal polyposis. Winnie-ApcMin/+ mice show an early occurrence of inflammatory signs and dysplastic lesions in the distal colon with a specific molecular signature. (4) Conclusion: The Winnie-ApcMin/+ model is a perfect model to demonstrate that chronic inflammation represents a crucial risk factor for the onset and progression of tumoral lesions in individuals genetically predisposed to CRC.

Keywords: Aberrant Crypt Foci; colorectal cancer; inflammation; murine model.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflicts of interest.

Figures

Figure 1
Figure 1
Creation and characterization of the Winnie-APCMin/+ murine model. (A) Breeding strategy used to obtain Winnie-APCMin/+ mice and the control littermates. (B) Impact of APCMin/+ mutation on survival rate in the breeding scheme of Winnie and Winnie-APCMin/+ mice. (C) Body weight analysis of 4-week-old Winnie-APCMin/+ mice and their relative controls. (DF) Representative images of colon (D) and data analysis of colon length, and (E) colon length adjusted to body weight (F) for Winnie-APCMin/+ mice and control lines sacrificed at 5 weeks. (E,F): n = 7 animals/group. * p < 0.05, *** p < 0.001 compared to WT mice.
Figure 2
Figure 2
Hematoxylin and eosin staining on 3μm colon sections from proximal (A), medial (B) and distal (C) tracts of 5-week-old Winnie-APCMin/+ mice. Images were captured at 10× (left) and 20× magnifications (right).
Figure 3
Figure 3
PAS staining on 3 μm sections from distal colon of 5-week-old WT (A), Winnie (B), APCMin/+ (C) and Winnie-APCMin/+ (D) mice. Images were captured at 20× magnification.
Figure 4
Figure 4
Molecular pathways activated in 5-week-old Winnie-APCMin/+ mice. The distal colon of Winnie-APCMin/+ mice (white bars) was analyzed by qPCR relative to Winnie (A) and APCMin/+ (B) mice (black bars) (n = 3–4 animals/group). Horizontal lines indicate common genes between the two comparisons. Histograms represent the mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 5
Figure 5
Histological analysis of 8-week-old Winnie-APCMin/+ mice. (A) Hematoxylin and eosin staining on 3μm distal colon sections. Images were captured at 10× (left) and 20× magnifications (right). (B) Dot plot shows CRC progression from 5 to 8 weeks for Winnie-APCMin/+ mice as mean ± SEM of dysplastic ACFs. (C) Histograms show dysplastic ACFs composition in terms of dimension and grading for Winnie-APCMin/+ mice at 5 and 8 weeks. 5-week: n = 8–10 animals/group; 8-week: n = 8 animals/group. *p < 0.05.

References

    1. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Balkwill F., Mantovani A. Inflammation and cancer: Back to Virchow? Lancet. 2001;357:539–545. doi: 10.1016/S0140-6736(00)04046-0. - DOI - PubMed
    1. Coussens L.M., Werb Z. Inflammation and cancer. Nature. 2002;420:860–867. doi: 10.1038/nature01322. - DOI - PMC - PubMed
    1. Cuzick J., Otto F., Baron J.A., Brown P.H., Burn J., Greenwald P., Jankowski J., La Vecchia C., Meyskens F., Senn H.J., et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: An international consensus statement. Lancet. Oncol. 2009;10:501–507. doi: 10.1016/S1470-2045(09)70035-X. - DOI - PubMed
    1. Abraham C., Cho J.H. Inflammatory bowel disease. N. Engl. J. Med. 2009;361:2066–2078. doi: 10.1056/NEJMra0804647. - DOI - PMC - PubMed

LinkOut - more resources